Bright Minds Biosciences (DRUG) Competitors $26.16 +0.17 (+0.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$26.27 +0.11 (+0.42%) As of 07/18/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. MGTX, GYRE, AUTL, PHAR, DAWN, ZVRA, MAZE, MRVI, IOVA, and URGNShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Autolus Therapeutics (AUTL), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Zevra Therapeutics (ZVRA), Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors MeiraGTx Gyre Therapeutics Autolus Therapeutics Pharming Group Day One Biopharmaceuticals Zevra Therapeutics Maze Therapeutics Maravai LifeSciences Iovance Biotherapeutics Urogen Pharma Bright Minds Biosciences (NASDAQ:DRUG) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership. Does the media refer more to DRUG or MGTX? In the previous week, MeiraGTx had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 1 mentions for MeiraGTx and 0 mentions for Bright Minds Biosciences. MeiraGTx's average media sentiment score of 0.55 beat Bright Minds Biosciences' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media. Company Overall Sentiment Bright Minds Biosciences Neutral MeiraGTx Positive Which has more risk and volatility, DRUG or MGTX? Bright Minds Biosciences has a beta of -6.01, indicating that its share price is 701% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Is DRUG or MGTX more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to MeiraGTx's net margin of -484.90%. Bright Minds Biosciences' return on equity of -14.56% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% MeiraGTx -484.90%-241.05%-62.93% Which has stronger earnings and valuation, DRUG or MGTX? Bright Minds Biosciences has higher earnings, but lower revenue than MeiraGTx. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-72.67MeiraGTx$33.28M20.81-$147.79M-$2.32-3.72 Do institutionals & insiders have more ownership in DRUG or MGTX? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 7.5% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate DRUG or MGTX? Bright Minds Biosciences presently has a consensus target price of $83.25, indicating a potential upside of 218.23%. MeiraGTx has a consensus target price of $24.00, indicating a potential upside of 178.42%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bright Minds Biosciences is more favorable than MeiraGTx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBright Minds Biosciences beats MeiraGTx on 10 of the 16 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.07M$2.96B$5.55B$9.41BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-72.6619.7528.0119.82Price / SalesN/A300.10432.6698.27Price / CashN/A42.5936.1658.27Price / Book28.437.678.125.65Net Income-$2.06M-$55.28M$3.25B$257.91M7 Day Performance5.44%4.85%1.68%3.38%1 Month Performance-7.20%11.70%7.30%11.11%1 Year Performance2,155.17%3.69%32.89%18.99% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences2.4394 of 5 stars$26.16+0.7%$83.25+218.2%+2,300.0%$183.07MN/A-72.66N/AMGTXMeiraGTx4.163 of 5 stars$8.89+5.0%$24.00+170.0%+84.6%$714.40M$33.28M-3.83300GYREGyre Therapeutics0.024 of 5 stars$7.61+1.6%N/A-52.3%$713.51M$105.76M380.6940AUTLAutolus Therapeutics2.6512 of 5 stars$2.65+7.3%$9.32+251.7%-44.6%$705.27M$10.12M-3.01330Positive NewsPHARPharming Group2.1359 of 5 stars$10.35+3.5%$30.00+189.9%+17.4%$704.12M$320.71M-51.75280News CoverageGap UpDAWNDay One Biopharmaceuticals2.5917 of 5 stars$6.93+2.1%$29.00+318.5%-57.3%$702.44M$161.92M-9.7660ZVRAZevra Therapeutics3.112 of 5 stars$12.79+2.1%$23.71+85.4%+89.5%$699.36M$23.61M-6.7320Analyst RevisionHigh Trading VolumeMAZEMaze TherapeuticsN/A$15.74+4.6%$23.50+49.3%N/A$689.41M$167.50M0.00121MRVIMaravai LifeSciences3.5297 of 5 stars$2.67-2.2%$6.64+148.6%-73.0%$679.94M$259.18M-2.34610Positive NewsIOVAIovance Biotherapeutics4.7495 of 5 stars$2.01+7.5%$12.22+508.1%-73.2%$671.20M$164.07M-1.62500Analyst DowngradeAnalyst RevisionGap UpHigh Trading VolumeURGNUrogen Pharma4.3322 of 5 stars$14.49+1.8%$32.86+126.8%-8.2%$668.13M$90.40M-4.56200 Related Companies and Tools Related Companies MeiraGTx Competitors Gyre Therapeutics Competitors Autolus Therapeutics Competitors Pharming Group Competitors Day One Biopharmaceuticals Competitors Zevra Therapeutics Competitors Maze Therapeutics Competitors Maravai LifeSciences Competitors Iovance Biotherapeutics Competitors Urogen Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.